Neuroblastoma Clinical Trial
Official title:
The Effect of Nurse Case Manager Model on Caregiver's Adaptation of Disease Uncertainty About Their Child With Neuroblastoma
Clinical Problem and Significance: The incidence of neuroblastoma is about 30 cases a year
in Taiwan. The five-year survival rate of neuroblastom is near 50% in Taiwan. Compared to
the survival rate in Western countries, the treatment in Taiwan needs more efforts to
improve. According to the report from the Childhood Cancer Foundation ROC, several children
with neuroblastoma did not complete their treatment and or not received the protocol. In
addition to the efforts in improving protocol, the reasons for those who drop-out and do not
receive complete treatment need the investigators more attention to think of.
Purpose of Study: The main purpose is to evaluate the effects of nurse case manager model on
caregivers' adaptation of disease uncertainty about then child with neuroblastorna.
Methods: A longitudinal and prospective design will be used to perform this study.
Questionnaire survey and chart review will be the means of data collection for the part of
quantative analysis. The qualitative method , semi-structural interview , also will be used
to collect data regarding caregiver's perception of social support and adaptation at the
same time of self-report of questionnaires survey .There are five points of time to collect
data: Baseline (A), 3 months(B) , 6 months(C), 9 months(D),1 year(E) and 1.5 year(F) after
eligible subjects agree to participate in the study.
Subjects: The study will use a convenience sample. Once the caregiver's child is on has been
diagnosed with neuroblastoma will be recruited in this study.
Instruments: Three Chinese versions of Mishel Uncertainty in Illness-Parent Form , the
self-reported socio-demographic questionnaire will be used to collect data. Process
recording will be typed once finishing interview for further analysis.
Data Analysis: Quantitative data will be analyzed using SPSS 15.0 statistical software. The
data will be analyzed using descriptive statistics and inferred statistics. Content analysis
and theme formation will be categorized to assist the interpretation of quantitative
results.
Implication: The findings of this study will be expected of the effects of nurse care
manager model on children with newoblastoma cancer survivors.
n/a
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00492167 -
Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma
|
Phase 1 | |
| Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
| Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03107988 -
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
|
Phase 1 | |
| Recruiting |
NCT04253015 -
A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta
|
||
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03273712 -
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
|
Phase 2 | |
| Recruiting |
NCT02933333 -
G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
|
Phase 4 | |
| Recruiting |
NCT00588068 -
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
|
||
| Recruiting |
NCT04301843 -
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
|
Phase 2 | |
| Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
| Recruiting |
NCT04040088 -
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
|
Early Phase 1 | |
| Recruiting |
NCT06057948 -
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
|
Phase 2 | |
| Not yet recruiting |
NCT06335745 -
PediCARE Health Equity Intervention in High-Risk Neuroblastoma
|
N/A | |
| Recruiting |
NCT02559778 -
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
|
Phase 2 | |
| Completed |
NCT02441062 -
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT02245997 -
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma
|
N/A | |
| Not yet recruiting |
NCT01156350 -
Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT01192555 -
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01222780 -
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
|
Phase 1 |